Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank

ObjectivesTo investigate the association between shingles and dementia, and between Zostavax vaccination and dementia.DesignNested case–control study.SettingsData were drawn from the UK Biobank cohort study with a total of 228 223 participants with Hospital Episodes Statistics and primary care linkage health records.ParticipantsThe analyses included 2378 incident dementia cases and 225 845 controls. Inclusion criteria for incident cases were a dementia diagnosis 3 years or more after the first assessment date derived from all sources including International Classification of Diseases (ICD)-10, ICD-9, self-report and primary care linkage records. Subjects with no dementia code from all sources were coded as controls. Both shingles and Zostavax vaccination were investigated for their association with dementia risk.ResultsThere was a small but non-significant increase in the risk of dementia in subjects with shingles diagnosed 3 years or more prior to dementia diagnosis (OR: 1.088 with 95% CI: 0.978 to 1.211). In those subjects who had had Zostavax vaccination, the risk of dementia significantly decreased (OR: 0.808 with 95% CI: 0.657 to 0.993).ConclusionA history of shingles was not associated with an increased risk of dementia. In subjects who were eligible for the immunisation and vaccinated with Zostavax, we saw reduced risk of developing dementia.

Download Full-text

Adherence to a healthy lifestyle and multiple sclerosis: a case–control study from the UK Biobank

Nutritional Neuroscience ◽

10.1080/1028415x.2020.1846357 ◽

2020 ◽

pp. 1-9

Author(s):

Nicola Veronese ◽

Lin Yang ◽

Laura Piccio ◽

Lee Smith ◽

Joseph Firth ◽

...

Keyword(s):

Multiple Sclerosis ◽

Case Control Study ◽

Healthy Lifestyle ◽

Case Control ◽

Uk Biobank ◽

The Uk ◽

Control Study

Download Full-text

Association between serum urate, gout and comorbidities: a case–control study using data from the UK Biobank

Rheumatology ◽

10.1093/rheumatology/keaa773 ◽

2020 ◽

Author(s):

Gabriela Sandoval-Plata ◽

Georgina Nakafero ◽

Mithun Chakravorty ◽

Kevin Morgan ◽

Abhishek Abhishek

Keyword(s):

Case Control Study ◽

Serum Urate ◽

Case Control ◽

Dietary Factors ◽

Uk Biobank ◽

Crystal Deposition ◽

Using Data ◽

Urate Lowering Treatment ◽

The Uk ◽

Control Study

Abstract Objectives To examine the association between comorbidities and serum urate (SU), gout and comorbidities, and to determine whether the association between gout and comorbidities is independent of SU. Methods We performed a case–control study using UK Biobank data. Two separate analyses were conducted: one excluding participants with gout to investigate the association between comorbidities and SU and the other with participants with gout as the index condition to examine the association between gout and comorbidities. SU was measured at the baseline visit. Self-reported physician-diagnosed illnesses were used to define gout and comorbidities, except for chronic kidney disease (CKD), which was defined using an estimated glomerular filtration rate cut-off. Participants prescribed urate-lowering treatment were also classified as gout. Logistic regression was used to examine associations. Odds ratios (ORs) and 95% CIs were calculated and adjusted for covariates including comorbidities and SU. Results Data for 458 781 UK Biobank participants were used to examine the association between comorbidities and SU. There was an association between hypertension, ischaemic heart disease (IHD), congestive cardiac failure (CCF), hyperlipidaemia, CKD and SU with and adjusted OR (aOR) of 1.10–3.14 for each 1 mg/dl SU increase. A total of 10 265 gout cases and 458 781 controls were included in the analysis of association between gout and comorbidities. Gout associated independently with hypertension, IHD, CCF, hyperlipidaemia and diabetes, with aORs of 1.21–4.15 after adjusting for covariates including SU. Conclusion Comorbidities associate with increasing SU. The association between gout and cardiometabolic comorbidities was independent of SU, suggesting separate SU-independent mechanisms such as inflammation driven by crystal deposition, pro-inflammatory genotype or non-purine dietary factors.

Download Full-text

A data-driven approach for studying the role of body mass in multiple diseases: a phenome-wide registry-based case-control study in the UK Biobank

The Lancet Digital Health ◽

10.1016/s2589-7500(19)30028-7 ◽

2019 ◽

Vol 1 (3) ◽

pp. e116-e126 ◽

Cited By ~ 6

Author(s):

Elina Hyppönen ◽

Anwar Mulugeta ◽

Ang Zhou ◽

Vimaleswaran Karani Santhanakrishnan

Keyword(s):

Body Mass ◽

Case Control Study ◽

Case Control ◽

Data Driven ◽

Uk Biobank ◽

Data Driven Approach ◽

The Uk ◽

Control Study

Download Full-text

Apolipoprotein E in Temporal Lobe Epilepsy: A Case-Control Study

Disease Markers ◽

10.1155/2006/951632 ◽

2006 ◽

Vol 22 (5-6) ◽

pp. 335-342 ◽

Cited By ~ 8

Author(s):

Amit Kumar ◽

Manjari Tripathi ◽

Ravindra M. Pandey ◽

Lakshmy Ramakrishnan ◽

M. Srinivas ◽

...

Keyword(s):

Temporal Lobe Epilepsy ◽

Apolipoprotein E ◽

Temporal Lobe ◽

Plasma Levels ◽

Case Control Study ◽

Apoe Genotype ◽

Case Control ◽

Apo E ◽

Relationship Of ◽

Control Study

Purpose:To investigate the relationship of apolipoprotein E (apoE) genotype, plasma levels of apoE and lipids in temporal lobe epilepsy (TLE) patients in Asian Indians. Status of plasma levels of Apo E in epilepsy patients has not been reported till date.Methods:ApoE gene polymorphism was analyzed in 58 patients with temporal lobe epilepsy (TLE) and 57 age and sex approximated controls using Polymerase chain reaction- restriction fragment length polymorphism (PCR-RFLP). Levels of plasma apoE and lipids were measured using ELISA and enzymatic kits respectively.Results:The distribution of ApoE genotype in epilepsy patients and controls was comparable. Higher levels of plasma ApoE were observed in TLE patients as compared to controls (p= 0.0001). Individuals with plasma levels of apoE > 190 mg/L were at 20 times higher odds (95%CI = 2.46–163.34,p= 0.005), while those with levels of apoE between 150–190 mg/L were at 4.9 times higher odds (95% CI = 1.85–13.9,p= 0.001), to develop TLE.Conclusions:We have observed for the first time, high levels of plasma apoE in epilepsy patients. The findings of this case-control study suggest that apolipoprotein E may play an important role in epilepsy.

Download Full-text

Age Modifies the Association Between Apolipoprotein E Genotype and Alzheimer's Disease: A CSF Biomarker-Based Multicentric Case-Control Study

SSRN Electronic Journal ◽

10.2139/ssrn.3417885 ◽

2019 ◽

Author(s):

Hana Sadikki ◽

Aurore Fayosse ◽

Emmanuel Cognat ◽

Séverine Sabia ◽

Sebastiaan Engelborghs ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Apolipoprotein E ◽

Case Control Study ◽

Case Control ◽

Csf Biomarker ◽

Control Study ◽

Apolipoprotein E Genotype

Download Full-text

Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England

Journal of Medical Microbiology ◽

10.1099/jmm.0.47690-0 ◽

2008 ◽

Vol 57 (4) ◽

pp. 480-487 ◽

Cited By ~ 29

Author(s):

Dona Foster ◽

Kyle Knox ◽

A. S. Walker ◽

D. T. Griffiths ◽

Hazel Moore ◽

...

Keyword(s):

Conjugate Vaccine ◽

Pneumococcal Disease ◽

Case Control Study ◽

Case Control ◽

Polysaccharide Vaccine ◽

Pneumococcal Polysaccharide Vaccine ◽

Matched Case ◽

The Uk ◽

Matched Case Control Study ◽

Control Study

A 10-year invasive pneumococcal disease (IPD) enhanced surveillance project in the Oxfordshire region of the UK between 1996 and 2005 identified a total of 2691 Streptococcus pneumoniae isolates from all ages that provided a comprehensive description of pneumococcal epidemiology. All isolates were serotyped and those from children under 5 years of age were genotyped and a matched case–control study using adults hospitalized between 1995 and 2000 was performed to estimate the effectiveness of the pneumococcal polysaccharide vaccine in the local population. Fifty-one serotypes were isolated, with different age distributions. The overall incidence of IPD was 9.2 cases per 100 000 population per annum [95 % confidence interval (CI), 8.6–9.9] and that of meningitis was 0.7 per 100 000 population per annum (95 % CI 0.5–0.9). After adjusting for age, serotype 1 was found to be less likely to be associated with meningitis versus other IPD, compared with the most common serotype 14, whereas serotype 12F was more likely to cause meningitis than other IPD. There were significant temporal changes in IPD incidence of four serotypes, with decreases in serotypes 1, 12F and 14 and increases in serotype 8. A possible novel variant (from serotype 6A to 6B) was found using multilocus sequence typing analysis. From the matched case–control study of adults, the pneumococcal polysaccharide vaccine effectiveness was estimated to be 43 % (2–68 %), which did not change significantly after adjustment for pre-existing co-morbidities. The data provide a baseline against which the impact of the pneumococcal conjugate vaccine introduced in the UK in 2006 could be measured.

Download Full-text